RxSight, Inc. (NASDAQ:RXST) Insider Ilya Goldshleger Sells 3,105 Shares

RxSight, Inc. (NASDAQ:RXST) insider Ilya Goldshleger sold 3,105 shares of the stock in a transaction on Friday, November 29th. The stock was sold at an average price of $46.08, for a total value of $143,078.40. Following the sale, the insider now owns 42,246 shares in the company, valued at approximately $1,946,695.68. This represents a 6.85 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Ilya Goldshleger also recently made the following trade(s):

• On Friday, November 22nd, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $45.00, for a total value of $139,500.00.
• On Tuesday, November 26th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $45.88, for a total value of $142,228.00.
• On Friday, November 15th, Ilya Goldshleger sold 4,875 shares of RxSight stock. The stock was sold at an average price of $46.00, for a total value of $224,250.00.
• On Monday, November 18th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $45.00, for a total value of $139,500.00.
• On Tuesday, November 12th, Ilya Goldshleger sold 1,330 shares of RxSight stock. The shares were sold at an average price of $46.13, for a total value of $61,352.90.
• On Wednesday, October 30th, Ilya Goldshleger sold 3,105 shares of RxSight stock. The shares were sold at an average price of $51.91, for a total value of $161,180.55.
• On Friday, October 25th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $49.79, for a total value of $154,349.00.
• On Monday, October 28th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $50.64, for a total value of $156,984.00.
• On Tuesday, October 22nd, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $49.68, for a total value of $154,008.00.
• On Friday, October 18th, Ilya Goldshleger sold 3,105 shares of RxSight stock. The shares were sold at an average price of $50.09, for a total value of $155,529.45.

RxSight Price Performance

Shares of RXST opened at $43.56 on Wednesday. RxSight, Inc. has a one year low of $29.97 and a one year high of $66.54. The company has a 50-day simple moving average of $48.47 and a two-hundred day simple moving average of $52.06. The firm has a market capitalization of $1.76 billion, a PE ratio of -52.48 and a beta of 1.11.

Institutional Trading of RxSight

Several institutional investors and hedge funds have recently bought and sold shares of RXST. CWM LLC lifted its holdings in RxSight by 727.5% in the second quarter. CWM LLC now owns 422 shares of the company’s stock worth $25,000 after buying an additional 371 shares during the period. Nisa Investment Advisors LLC lifted its holdings in shares of RxSight by 854.1% during the third quarter. Nisa Investment Advisors LLC now owns 582 shares of the company’s stock valued at $29,000 after purchasing an additional 521 shares during the last quarter. Quarry LP lifted its holdings in shares of RxSight by 82.3% during the third quarter. Quarry LP now owns 638 shares of the company’s stock valued at $32,000 after purchasing an additional 288 shares during the last quarter. Point72 Hong Kong Ltd purchased a new position in shares of RxSight during the third quarter valued at approximately $34,000. Finally, Quest Partners LLC purchased a new position in shares of RxSight during the second quarter valued at approximately $41,000. 78.78% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the company. Jefferies Financial Group assumed coverage on RxSight in a research note on Tuesday, October 29th. They set a “buy” rating and a $72.00 price objective on the stock. Needham & Company LLC reissued a “buy” rating and issued a $66.00 target price on shares of RxSight in a research note on Friday, September 13th. Wells Fargo & Company cut their target price on RxSight from $68.00 to $54.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 6th. Stifel Nicolaus cut their target price on RxSight from $70.00 to $65.00 and set a “buy” rating on the stock in a research note on Tuesday, August 6th. Finally, Oppenheimer cut their target price on RxSight from $72.00 to $65.00 and set an “outperform” rating on the stock in a research note on Tuesday, August 6th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, RxSight has a consensus rating of “Buy” and an average price target of $61.63.

RxSight Company Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.